Biogen Inc. (NASDAQ:BIIB – Get Free Report) saw some unusual options trading on Tuesday. Traders bought 6,120 put options on the company. This represents an increase of approximately 232% compared to the average volume of 1,846 put options.
Biogen Trading Down 0.8%
Shares of NASDAQ:BIIB traded down $1.98 during mid-day trading on Tuesday, hitting $249.68. The company had a trading volume of 371,369 shares, compared to its average volume of 1,203,917. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. The firm has a fifty day moving average price of $233.96 and a 200 day moving average price of $205.42. The company has a market capitalization of $36.91 billion, a PE ratio of 106.68, a price-to-earnings-growth ratio of 2.84 and a beta of 0.10. Biogen has a one year low of $160.36 and a one year high of $261.00.
Biogen (NASDAQ:BIIB – Get Free Report) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. During the same period last year, the business posted $4.81 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, research analysts forecast that Biogen will post 12.46 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Biogen by 830.1% in the third quarter. State Street Corp now owns 136,622,812 shares of the biotechnology company’s stock valued at $30,860,361,000 after acquiring an additional 121,934,158 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Biogen during the second quarter valued at approximately $3,453,878,000. Primecap Management Co. CA acquired a new stake in Biogen in the 2nd quarter valued at about $3,274,304,000. Public Sector Pension Investment Board boosted its position in shares of Biogen by 10,085.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company’s stock valued at $557,042,000 after acquiring an additional 2,441,884 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Biogen by 1,524.5% in the third quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after acquiring an additional 2,041,161 shares during the period. Institutional investors own 87.93% of the company’s stock.
Latest Biogen News
Here’s some of the latest news about BIIB:
- Positive Sentiment: Biogen entered a research collaboration with TRIMTECH Therapeutics to discover and develop small-molecule protein degraders for neurodegenerative diseases. The deal may expand Biogen’s research pipeline, although programs remain early-stage and the supplied report does not specify financial terms. TRIMTECH collaboration announcement
- Positive Sentiment: Wall Street Zen upgraded Biogen, adding a favorable analyst signal, though the report does not provide the rationale or rating details. Wall Street Zen upgrade
- Negative Sentiment: Traders bought 6,120 BIIB put options, 232% above the average daily volume of 1,846. The activity may reflect hedging or bearish expectations, but options volume alone does not establish a market direction.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on BIIB shares. TD Cowen boosted their target price on Biogen from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Wall Street Zen raised Biogen from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company increased their price objective on shares of Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 20th. Citigroup reiterated a “neutral” rating on shares of Biogen in a research report on Wednesday, October 28th. Finally, Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $254.41.
Read Our Latest Stock Analysis on BIIB
About Biogen
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Stories
- Five stocks we like better than Biogen
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
